ArticleGastro hep advances2025
Nonselective Beta-Blocker Associated With Decreased Mortality in Patients With Gastric Varices.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gastric varices: a contemporary review of vascular anatomy and therapeutic strategies.BMJ open gastroenterology · 2026Review
- Nonselective Beta Blockers Are Beneficial in Patients with Cirrhotic Ascites and Spontaneous Bacterial Peritonitis: A Propensity-Matched Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Gastric varices (GV) are a less common complication of portal hypertension than esophageal varices but are associated with higher mortality when hemorrhage occurs. While nonselective beta-blockers (NSBBs) have been extensively studied for the primary and secondary prevention of esophageal variceal hemorrhage, data on their efficacy in preventing gastric variceal hemorrhage remain limited. This study investigates the impact of NSBBs on clinical outcomes in patients with GV. Methods: We conducted a retrospective cohort study of patients aged 18-75 years diagnosed with GV between January 1, 2015, and July 31, 2021, within an integrated healthcare system in Southern California. The cohort was followed until February 28, 2022. Outcomes, including gastric variceal hemorrhage, esophageal variceal hemorrhage, liver transplantation, transjugular intrahepatic portosystemic shunt placement, and mortality, were compared between NSBB users and nonusers using multivariate logistic regression analyses. Results: A total of 1276 patients with GV were identified, including 767 (62.5%) on NSBBs and 509 (41.5%) not receiving NSBBs. After a 7-year follow-up, mortality was lower in the NSBB group (39.2%) than in the non-NSBB group (50.9%) (OR = 0.62; 95% CI: 0.46-0.84). No significant differences were observed between groups for other clinical outcomes. The overall mortality rate at study completion was 40.1%. Conclusion: In our study, NSBB use in patients with GV was associated with reduced mortality, suggesting a potential prognostic benefit in real-world clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.